796848-79-8

Basic information

• Product Name: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea
• Synonyms: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea;N-(2-chloro-4-hydroxyphenyl)-N'-cyclopropyl-Urea;Urea, N-(2-chloro-4-hydroxyphenyl)-N'-cyclopropyl-;Lenvatinib Impurity a;(Z)-N-(2-chloro-4-hydroxyphenyl)-N-cyclopropylcarbamimidic acid;Lenvatinib Impurity 6;lenvaint-I
• CAS NO: 796848-79-8
• Molecular Formula: C10H11ClN2O2
• Molecular Weight: 226.65954
• Mol File: 796848-79-8.mol

Chemical Properties

• Boiling Point: 364.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3 (20 oC 760 Torr), Calc.*
• Storage Temp.: 2-8°C
• PKA: 9.37±0.31(Predicted)
• CAS DataBase Reference: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(796848-79-8)
• EPA Substance Registry System: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(796848-79-8)

Safety Data

• Hazardous Substances Data: 796848-79-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea is used as an active pharmaceutical ingredient for the development of cancer treatment drugs. It targets multiple receptor tyrosine kinases, such as VEGF, FGF, and SCF receptors, which are involved in tumor growth and angiogenesis. By inhibiting these receptors, it helps in controlling the progression of cancer and improving the therapeutic outcomes for patients.
Used in Oncology Research:
1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea is used as a research compound in oncology studies. It aids in understanding the molecular mechanisms of receptor tyrosine kinases and their role in cancer progression. This knowledge can contribute to the development of novel therapeutic strategies and targeted cancer treatments.
Used in Drug Development:
1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea is used as a lead compound in drug development for the treatment of various types of cancer. Its ability to inhibit multiple receptor tyrosine kinases makes it a promising candidate for the development of new drugs with potential synergistic effects and improved efficacy in cancer therapy.

Upstream product

• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 1885-14-9 phenyl chloroformate 
• 765-30-0 Cyclopropylamine 
• 4333-56-6 cyclopropyl bromide 
• 17609-80-2 4-amino-3-chlorophenol 
• 796848-80-1 phenyl N-(2-chloro-4-hydroxyphenyl)carbamate 
• 1033090-34-4 N-cyclopropyl-1H-imidazole-1-carboxamide 

Downstream Products

• 417722-93-1 4?(4?amino?3?chlorophenoxy)?7?methoxyquinoline?6?carboxamide 

Relevant articles and documents

UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a urea-substituted aromatic ring-linked dioxane-quinazoline compound of Formula (I) and a urea-substituted aromatic ring-linked dioxane-quinoline, or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.

Method for refining Lenvatinib mesylate

The invention discloses a method for refining Lenvatinib mesylate. The method for refining the Lenvatinib mesylate, provided by the invention, comprises the following step: subjecting a solution formed by an organic solvent and crude Lenvatinib mesylate t

Isotope enrichment lenvatinib

The invention discloses isotope enrichment lenvatinib, a pharmaceutically acceptable salt form thereof, and a treatment method using the isotope enrichment lenvatinib, and specifically relates to an isotope enrichment compound represented by a formula I o

PROCESS FOR THE PREPARATION OF LENVATINIB

The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.

A [...] synthetic method

The invention provides a method of synthesizing [...]. First of all the invention to 4 - cyano - 3 - hydroxy aniline as the starting material, by dimethyl carbonate methylation, after third acid in the oximation reaction at room temperature, the conditions in the PPA shut-ring forms the 6 - cyano - 7 - methoxy - 4 - quinolinone, in thionyl chloride formed under the action of the 6 - cyano - 7 - methoxy - 4 - [...], under acidic conditions [...] cyano hydrolysis synthesis of one of the intermediates 6 - formamido - 7 - methoxy - 4 - chloroquinolin. Then the 4 - hydroxy - 2 chloroaniline with cyanogen bromide at low temperature 4 - hydroxy - 2 - chloro cyaniding amine, the 4 - hydroxy - 2 - chloro cyaniding amine with bearing-displacement generating Reeth reaction synthesis [...] another key intermediate 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea. Finally the two intermediate 6 - formamido - 7 - methoxy - 4 - chloroquinolin and 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea in the alkaline environment for carrying out the alkylation reaction [...]. This scheme has mild reaction conditions, no highly toxic reagent, environmental protection and the like.

Method for synthesizing lenvatinib

The invention belongs to the field of chemical pharmacy, and specifically relates to a method for synthesizing lenvatinib. The method comprises the following steps: step 1, taking 4-aminosalicylic acid as a raw material, and preparing 4-chloro-7-methoxyquinoline-6-formamide through methylation, condensation with meldrum's acid, high-temperature cyclization, chlorination and ammoniation; step 2, taking 3-chloro-4-aminophenol as a raw material, and reacting with phenyl chloroformate and cyclopropylamine to obtain 1-(2-chloro-4-hydroxy phenyl)-3-cyclopropyl urea; and step 3, enabling the 4-chloro-7-methoxyquinoline-6-formamide prepared in step 1 to react with the 1-(2-chloro-4-hydroxy phenyl)-3-cyclopropyl urea prepared in step 2 under action of potassium tert-butoxide to obtain the lenvatinib. The invention provides a brand-new route for synthesising the lenvatinib. The used reagent is cheap and is easily available, is simple in operation, has a yield higher than that of other methods, and is easy for industrial production.

Substituted urea compound and pharmaceutically acceptable salts or solvates thereof, application for substituted urea compound and pharmaceutically acceptable salts or solvates of substituted urea compound, and pharmaceuticals and pharmaceutical compositi

The invention provides a substituted urea compound, and pharmaceutically acceptable salts or solvates thereof. The invention also provides an application of the substituted urea compound, the pharmaceutically acceptable salts or the solvates of the substi

[...] intermediate and its preparation and [...] preparation (by machine translation)

The present invention relates to the field of drug synthesis, discloses a [...] key intermediate 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea and its preparation and [...] preparation. The music-cutting of the Buddhist intermediate, its pu

Deuterated compound, salt, preparation method, drug composition and application thereof

The invention discloses a compound with the structure shown in the formula (I) and pharmacologically acceptable salt. The invention further provides a preparation method of the compound shown in the formula (I) and a drug composition containing the compou

Preparation method of lenvatinib

The invention belongs to the field of medical chemistry, and provides a preparation method of a compound of lenvatinib. The method is characterized by comprising the following steps that (1) under the existence of an organic solvent and an alkali reagent,